Scopio Labs extends Series D with additional $10 million
The company’s round totals $52 million and will help advance its automated blood morphology technology.
Scopio Labs has secured an additional $10 million investment from Viola Growth to accelerate the rollout of its Complete Blood Morphology (CBM) analyzer, a new AI-powered solution designed to automate one of the most labor-intensive steps in hematology diagnostics. The new funding brings Scopio’s total Series D round to $52 million.
The company says the CBM analyzer can autonomously analyze peripheral blood smears (PBS), which are currently reviewed manually in labs, even as other processes like Complete Blood Counts (CBCs) have been automated for years. PBS review remains time-consuming, variable, and dependent on skilled personnel, and a challenge that has only intensified amid a global shortage of lab professionals and increased demand for diagnostic testing.
“Our vision is to be the first to close the automation gap in hematology by developing a fully integrated and automated hematology process from CBC to final result,” said Itai Hayut, CEO and Co-founder at Scopio Labs. “This isn't just a small step forward, it could potentially reshape the whole market by changing the workflow, the economics, and creating an entirely new market category. With CBM, the market can evolve from current digital lab solutions that help people make decisions, to a system that's designed to deliver fully automated results with the goal of eliminating the need for routine human morphology review altogether. Beyond that, we also believe that this technology will pave the way to developing accurate and consistent morphology-based biomarkers and diagnostic panels, which can be used for early detection and monitoring of disease directly from blood.”
The CBM system uses computational imaging and AI to examine 10x more cells than traditional methods. According to the company, this creates a more standardized and scalable process for labs. Scopio says labs already using its Full-Field PBS platform are positioned for easier adoption of CBM once it becomes available.
Scopio Labs has received CE and FDA clearance for digital imaging platforms used in blood smear and bone marrow aspirate analysis. However, the CBM system is still under development and is not yet available for in vitro diagnostic use. The company will present the new analyzer at the ADLM 2025 Annual Conference in Chicago later this month.
“We’re excited to join Scopio on their journey to reshape the future of hematology diagnostics,” added Igal Shany, General Partner at Viola Growth. “Scopio’s CBM analyzer represents a major leap forward for hematology labs, delivering autonomous morphology review with the depth, speed, and scalability this critical step urgently needs.”
